Modus Therapeutics Overview

  • Year Founded
  • 2004

Year Founded

  • Status
  • Public

  • Employees
  • 2

Employees

  • Stock Symbol
  • MODTX

Stock Symbol

  • Share Price
  • $0.02
  • (As of Friday Closing)

Modus Therapeutics General Information

Description

Modus Therapeutics Holding AB is a Swedish biotechnology company developing its patented polysaccharide, sevuparin, as a potential treatment for unmet medical needs. Its research focuses on conditions involving severe systemic inflammation, including sepsis and septic shock, severe malaria, and other related disorders, as well as anemia associated with chronic inflammatory conditions such as kidney disease.

Contact Information

Website
www.modustx.com
Formerly Known As
Dilaforette
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • Olof Palmes Gata 29 IV
  • 111 22 Stockholm
  • Sweden
+46 08-502
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
STO
Vertical(s)
Corporate Office
  • Olof Palmes Gata 29 IV
  • 111 22 Stockholm
  • Sweden
+46 08-502

Modus Therapeutics Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Modus Therapeutics Stock Performance

As of 13-Nov-2026, Modus Therapeutics’s stock price is $0.02. Its current market cap is $2.91M with 169M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.02 $0.02 $0.02 - $0.06 $2.91M 169M 1.21M -$0.02

Modus Therapeutics Financials Summary

As of 30-Jun-2026, Modus Therapeutics has a trailing 12-month revenue of null.

In Thousands,
USD
TTM 30-Jun-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 5,041 2,225 5,167 7,703
Revenue 0 0 0 0
EBITDA (1,867) (1,847) (1,498) (1,543)
Net Income (1,878) (1,887) (1,470) (1,684)
Total Assets 1,366 1,379 443 2,005
Total Debt 0 0 0 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Modus Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Modus Therapeutics‘s full profile, request access.

Request a free trial

Modus Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Modus Therapeutics‘s full profile, request access.

Request a free trial

Modus Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Modus Therapeutics Holding AB is a Swedish biotechnology company developing its patented polysaccharide, sevuparin, as a
Drug Discovery
Stockholm, Sweden
2 As of 2026

Plymouth Meeting, PA
 

Amsterdam, Netherlands
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Modus Therapeutics Competitors (25)

One of Modus Therapeutics’s 25 competitors is Inovio Pharmaceuticals, a Corporation company based in Plymouth Meeting, PA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Inovio Pharmaceuticals Corporation Plymouth Meeting, PA
uniQure Formerly VC-backed Amsterdam, Netherlands
Xalud Therapeutics Venture Capital-Backed New York, NY
Galectin Therapeutics Corporation Norcross, GA
Supernus Formerly VC-backed Rockville, MD
You’re viewing 5 of 25 competitors. Get the full list »

Modus Therapeutics Patents

Modus Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
GB-202314100-D0 New medical use Inactive 15-Sep-2023
GB-202302278-D0 New medical use Inactive 17-Feb-2023
GB-2627263-A New medical use Inactive 17-Feb-2023
EP-4665360-A1 New medical use of sevuparin in the treatment of endotoxemia Pending 17-Feb-2023
US-20260232720-A1 New medical use of sevuparin in the treatment of endotoxemia Pending 17-Feb-2023 A61K31/727
To view Modus Therapeutics’s complete patent history, request access »

Modus Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Modus Therapeutics Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Modus Therapeutics‘s full profile, request access.

Request a free trial

Modus Therapeutics ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Biotechnology

Subindustry

Rank

Percentile

To view Modus Therapeutics’s complete esg history, request access »

Modus Therapeutics FAQs

  • When was Modus Therapeutics founded?

    Modus Therapeutics was founded in 2004.

  • Where is Modus Therapeutics headquartered?

    Modus Therapeutics is headquartered in Stockholm, Sweden.

  • What is the size of Modus Therapeutics?

    Modus Therapeutics has 2 total employees.

  • What industry is Modus Therapeutics in?

    Modus Therapeutics’s primary industry is Drug Discovery.

  • Is Modus Therapeutics a private or public company?

    Modus Therapeutics is a Public company.

  • What is Modus Therapeutics’s stock symbol?

    The ticker symbol for Modus Therapeutics is MODTX.

  • What is the current stock price of Modus Therapeutics?

    As of 13-Nov-2026 the stock price of Modus Therapeutics is $0.02.

  • What is the current market cap of Modus Therapeutics?

    The current market capitalization of Modus Therapeutics is $2.91M.

  • Who are Modus Therapeutics’s competitors?

    Inovio Pharmaceuticals, uniQure, Xalud Therapeutics, Galectin Therapeutics, and Supernus are some of the 25 competitors of Modus Therapeutics.

  • What is Modus Therapeutics’s annual earnings per share (EPS)?

    Modus Therapeutics’s EPS for 12 months was -$0.02.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process